Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib vs BAT in Steroid-Refractory Chronic GVHD
NCT03112603Phase 3Completed
- Sponsor
- Incyte
- Start
- Jun 2017
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 31
01
Overview
A Phase 3 trial of ruxolitinib in chronic graft-versus-host disease (cGVHD), sponsored by Incyte. Started Jun 2017; status: completed.
02
Drugs
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT03112603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03112603.